Shares of uniQure fell over 35% on March 2, 2026, after the U.S. FDA said the clinical data supporting the company’s AMT-130 gene therapy for Huntington’s disease was insufficient to support a marketing application, and recommended that the company conduct an additional study. The March 2nd decline follows an earlier drop of as much as 66% on November 3, 2025, when the company disclosed prior FDA feedback regarding the adequacy of its clinical data. A securities class action has been filed in the U.S. District Court for the Southern District of New York alleging that uniQure and certain executives misled investors about the strength of the clinical results and the therapy’s regulatory prospects during the period from September 24, 2025, through October 31, 2025.
Contact our attorneys for a no-cost case evaluation.